medRxiv preprint doi: https://doi.org/10.1101/2021.07.19.21258470; this version posted July 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

1	¹ H-NMR metabolomics-based surrogates to impute common
2	clinical risk factors and endpoints
3 4 5	D. Bizzarri ^{1,2} , M.J.T. Reinders ^{2,3} , M. Beekman ¹ , P.E. Slagboom ^{1,4} , BBMRI-NL ⁵ and E.B. van den Akker ^{1,2,3, #}
4 5 6 7 8 9 10 11	¹ Molecular Epidemiology, LUMC, Leiden, The Netherlands ² Leiden Computational Biology Center, LUMC, Leiden, The Netherlands ³ Delft Bioinformatics Lab, TU Delft, Delft, The Netherlands ⁴ Max Planck Institute for the Biology of Ageing, Cologne, Germany ⁵ BBMRI-NL: <u>https://www.bbmri.nl</u> ; see Consortium Banner Supplement S1
12 13 14 15 16 17	Material & correspondence (#) Erik B. van den Akker, PhD; Leiden Computational Biology Center, Leiden University Medical Center, Leiden, The Netherlands; Einthovenweg 20, 2333 ZC, Leiden, The Netherlands; Tel: +31 (0)71 526 85 57; Fax: +31 (0)71 526 82 80; E-mail: e.b.van_den_akker@lumc.nl; website: <u>http://www.lcbc.nl</u>
18 19	ABSTRACT
20	Missing or incomplete phenotypic information can severely deteriorate the statistical power in
21	epidemiological studies. High-throughput quantification of small-molecules in bio-samples,
22	i.e. 'metabolomics', is steadily gaining popularity, as it is highly informative for various
23	phenotypical characteristics. Here we aim to leverage metabolomics to impute missing data in
24	clinical variables routinely assessed in large epidemiological and clinical studies. To this end,
25	we have employed ~25,000 ¹ H-NMR metabolomics samples from 28 Dutch cohorts collected
26	within the BBMRI-NL consortium, to create 19 metabolomics-based predictors for clinical
27	variables, including diabetes status (AUC _{5-Fold CV} = 0.94) and lipid medication usage (AUC ₅₋
28	$_{Fold CV}$ = 0.90). Subsequent application in independent cohorts confirmed that our
29	metabolomics-based predictors can indeed be used to impute a wide array of missing clinical
30	variables from a single metabolomics data resource. In addition, application highlighted the
31	potential use of our predictors to explore the effects of totally unobserved confounders in omics
32	association studies. Finally, we show that our predictors can be used to explore risk factor
33	profiles contributing to mortality in older participants. To conclude, we provide ¹ H-NMR
34	metabolomics-based models to impute clinical variables routinely assessed in epidemiological
35	studies and illustrate their merit in scenarios when phenotypic variables are partially
36	iNCTE: This preprint reparts new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.07.19.21258470; this version posted July 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.


37 INTRODUCTION

38 A major goal in biomedical research is to find faithful biomarkers of health, defined as 39 accurate and reproducible assays that provide objective indications on the health of an 40 individual and his/her risk of developing a disease over predefined time trajectory [1]. Over 41 the years, many types of putative biomarkers have been proposed, ranging from environmental 42 factors to biochemical assays, that may aid the diagnosis and prognostication of disease, 43 including cardiovascular disease, cancer and immunological disorders. Many of these clinical 44 variables, however, are costly or cumbersome to obtain, especially for more critical and frail 45 participants, such as older individuals [2], [3]. Consequently, missing data frequently occurs in large epidemiological or clinical studies, potentially leading to a significant loss of statistical 46 47 power, thus impeding biomarker research in studies of older individuals [4].

48 Missing phenotypic data can be handled in various ways. Often, analyses are either 49 restricted to individuals or variables with complete data, which both may introduce potential 50 biases [5]. Alternatively, missing data can be imputed using complete phenotypic variables [4], 51 [6]–[8], yet these approaches work only satisfactory if the complete phenotypic variables are 52 informative for the ones with missing observations. A third solution basically extents the 53 second approach by leveraging informative omics data to impute missing phenotypic data. 54 Particularly useful in this context are metabolite quantifications in minimally invasive 55 biomaterials, such as urine, saliva or blood plasma, obtained with proton Nuclear Magnetic 56 Resonance (¹H-NMR) assays [9]. Although this technique only captures a modest number of analytes, ¹H-NMR metabolomics data is frequently acquired in large-scale epidemiological 57 58 studies, as it is a cost-efficient and reproducible data resource. The underlying motivation is 59 that metabolite concentrations in blood seem to be direct readouts of various biological processes, incorporating cues of the environment as well as the host's genetic background, and 60 61 hence may be regarded as intermediate phenotypes. Indeed, metabolomics has been shown to

62 capture information on the effect of drug treatments [10], disease status [11]–[14], functional 63 and cognitive decline [15], and aging [16], [17]. In addition, several studies used the blood 64 metabolome to predict single anthropometric measures, i.e. BMI [18], or other physiological 65 characteristics, i.e. sex [19] or age [16]. However, it remains unclear whether the blood 66 metabolome captured by ¹H-NMR could represent phenotypic information over a wider set of 67 conventional clinical variables.

We hypothesize that a single set of blood metabolic markers combined in multiple 68 69 algorithms may represent a range of conventional clinical variables. As a proof of concept, we 70 generated metabolic surrogates for 20 variables of general clinical and epidemiological interest 71 available in at least 6 of the cohorts collaborating in BBMRI-NL. Here we will designate these 72 as conventional clinical variables and they comprehend physiological measures (sex, age, 73 blood pressure, etc.), environmental exposures (current smoking, etc.), body composition 74 measures (BMI, etc.), inflammatory factors (hsCRP), medication usage (lipids medication, 75 etc.), blood composition (white cell counts, etc.) lipids metabolism (LDL-cholesterol, etc.) and 76 cardiometabolic clinical endpoints (diabetes and metabolic syndrome). Acquiring data for all 77 these variables is costly and requires sufficient biomaterial, meaning that not every study has 78 collected the same set of data. We further explored these methods to establish metabolic 79 surrogate values in the Leiden Longevity Study, which we used to showcase possible 80 applications in epidemiological research. We showed the validity of the surrogates in an 81 external cohort comparing them to the original values, we examined their association to further 82 clinically valuable cardiometabolic health markers, and explored whether the metabolic 83 surrogates associate, separately or combined, to all-cause mortality.






Figure 1: Study design. [A] Upper panel: Training of ¹H-NMR metabolomics-based predictors for routinely assessed phenotypic variables available in BBMRI.nl. This data set was created as a collaboration of 28 community and hospital-based cohorts that collected nuclear magnetic resonance (¹H-NMR) metabolomics data (Nightingale) for ~31,000 individuals. Upper panel left: Metabolomics-based predictors were trained using an inner loop of 5-fold Cross Validation (CV) (with 5 repetitions) for hyperparameter optimization and were evaluated in unseen data employing an outer loop of 5-fold CV or Leave-One-Biobank-Out-Validation (LOBOV). Upper panel right: using our models 19 different surrogate values can be derived from a single metabolomics data measurement to impute or complement a broad set of conventional clinical variables routinely assessed in epidemiological and clinical studies. Lower panel: Trained metabolomics-predictors were evaluated in two application scenarios using a held-out study, the Leiden Longevity Study [20]. This study is a two-generation family-based cohort consisting of highly aged parents (LLS-SIBS, N = 817, median age = 92 years) and their middle-aged offspring and the partners thereof (LLS-PAROFF, N = 2,280, median age = 59 years), for which we had access to additional detailed phenotypic information. Trained predictors were evaluated for their ability to reconstruct missing datapoints in an independent dataset (Application 1, lower left), to be used as confounder in Metabolome Wide Association Studies (Application 2, lower central), and to investigate and to explore determinants of health in older individuals (Application 3, lower right). [B] Groupings of phenotypic variables routinely assessed in epidemiological and clinical studies for which data was available in BBMRI-NL. Continuous variables are dichotomized at levels generally accepted to confer an increased risk for cardio-metabolic endpoints. As various cutoffs on chronological age are in use, in part reflecting the highly non-linear relation between chronological age and disease risk, we choose to split chronological age in three categories (I 'young': <45 years [TRUE/FALSE]; II 'middleaged': ≥ 45 years [TRUE/FALSE]] and III 'old': < 65 years [TRUE/FALSE]]; ≥ 65 years). We integrated Body Mass Index, waist circumference and sex into one sex-specific measure of 'obesity'. Similarly, we integrated diastolic blood pressure (DBP) and systolic blood pressure to arrive at one variable 'high pressure'. Overall, we obtain data for 20 dichotomous phenotypic variables. Colors indicate groupings.

104
105
106Through the paper, we indicated some of the clinical variables with the following abbreviation: BMI=Body Mass Index, med=medication,
e.g.: lipid or blood pressure lowering medication, hsCRP=high-sensitivity C-Reactive Protein, eGFR=estimated Glomerular Filtration Rate,
chol=cholesterol, hgb=haemoglobin, wbc=white blood cells.

107 **RESULTS**

¹H-NMR metabolomics can be used to successfully predict 19 out of 20 clinical variables routinely measured in epidemiological and clinical studies

110 Missing or incomplete phenotypic information can severely deteriorate the statistical power 111 in epidemiological studies. Here we evaluate the ability of Nuclear Magnetic Resonance (¹H-112 NMR) metabolomics (Nightingale Health[©], Helsinki, Finland) to reconstruct conventional 113 clinical variables. For this purpose, we trained and evaluated prediction models (Figure 1A) 114 for 20 conventional clinical variables (Figure 1B) using data of ~31,000 individuals collected within the Dutch Biobanking and BioMolecular resources and Research Infrastructure 115 116 (BBMRI-NL: https://www.bbmri.nl/). Out of 220 metabolomic variables measured on the 117 platform, we employed 56 metabolic markers, selected to be the most uncorrelated [21], [22] and most successfully measured in the BBMRI studies (Methods and Supplementary 118 119 Materials). Conventional clinical variables were transformed or constructed with the emphasis 120 to be able to capture clinically relevant aspects of disease risk. For instance, we dichotomized 121 continuous variables according to generally accepted clinical thresholds, thus obtaining for each of these clinical variables an 'at risk' [TRUE/FALSE] variable. For the same purpose, 122 123 some variables were either merged or split. For instance, a sex-specific 'obesity' 124 [TRUE/FALSE] variable was defined using body mass index, waist circumference and sex, 125 whereas chronological age was split into three categories (Figure 1B). Overall, we were able 126 to construct and evaluate 20 variables mainly representing risk factors of cardio-metabolic 127 health that are routinely assessed in epidemiological and clinical studies.

Logistic Elastic-NET regression models were trained for each of the 20 dichotomous variables, measured in at least 6 of the BBMRI studies, in both healthy and diseased individuals. Model development was performed in two loops to prevent overtraining. An *inner* loop of 5-Fold Cross Validation with 5 repetitions was used to tune the hyperparameters of the 132 model. Model performances where then evaluated in an outer loop of held out data, using again 133 a 5-Fold CV or a Leave-One-Biobank-Out-Validation (LOBOV) (Figure 1A, Methods). We assessed model performances using the mean Area Under the Curve (AUC) of the receiver-134 135 operator curve obtained in the outer 5-Fold CV (Table 1) and considered a model's 136 performance to be sufficiently accurate at AUC > 0.7. Overall, 19 out of 20 models passed this 137 criterium, with only a single phenotypic variable, 'high-pressure', that could not be accurately 138 captured by ¹H-NMR (AUC_{5-Fold CV} = 0.68). Strikingly, 9 out of 20 models achieved an AUC₅₋ 139 $_{Fold CV} > 0.9$. While some of these high performances are expected as they directly relate to 140 metabolic markers assessed on the platform ('Low eGFR', 'high triglycerides', 'high LDL 141 cholesterol', 'high total cholesterol', and 'low LDL cholesterol'), this is not the case for four 142 other high performing models: 'diabetes' (AUC_{5-Fold CV} = 0.94), 'metabolic syndrome' (AUC₅₋ 143 Fold CV = 0.93), 'sex' (AUC_{5-FoldCV} = 0.92), 'lipid medication' (AUC_{5-FoldCV} = 0.90). Also, other important cardio-metabolic health statuses, including 'obesity', 'high CRP' and 'blood 144 pressure lowering medication' were predicted at a more than satisfactory accuracy (AUC_{5-Fold} 145 146 $_{\rm CV} > 0.8$), indicating that overall, the ¹H-NMR metabolome can be used to impute a broad 147 spectrum of common clinical variables.

148 As the performances of our models may vary per biobank due to study-specific characteristics, e.g. varying study inclusion criteria or protocols for sample storage, we also 149 150 evaluated the variation of our model performances across biobanks. First, using a Leave-One-151 Biobank-Out-Validation (LOBOV), we evaluate how our models would perform when applied 152 to data of a new unseen biobank. As expected, mean model accuracies of the LOBOV, 153 weighted based on the size of the testing biobank, show more variation across folds (Figure 154 S2A-B) and are generally slightly lower than the overall results of the 5-Fold CV (Table 1). In particular, some of the smaller studies containing diseased patients showed relatively poor 155 156 accuracies (Figure S2B). Indeed, surrogate values do show cohort specific effects, but 157 interestingly, this does not necessarily affect its predictive performance within cohorts (Figure

158 S2C). Overall, 14 out of the 20 models performed on average satisfactorily (AUC_{LOBOV} > 0.7)

159 across all studies in the LOBOV setting.

Table 1 | Performances of the 20 metabolic predictors

Table 1 Performances of the 20 met	abone preur			Dogulto			
				Results (AUC)			
Binary Outcomes		#	# True	5-Fold CV	LOBOV		
(threshold)	# samples	cohorts	positives	(mean)	(weighted mean)		
Low eGFR							
$(eGFR \le 60 \text{ ml/min} [23])$	21,439	23	1,196 (5.6%)	0.99 [0.98-0.99]	0.97 [0.91-0.99]		
High triglycerides	12 401	11	4 645 (42 20/)				
$(trig \ge 2.3 \text{ mmol/L } [24])$	13,401	11	1,645 (12.3%)	0.97 [0.97-0.98]	0.95 [0.84-0.99]		
High LDL cholesterol	13,261	11	2,051 (15.5%)	0.96 [0.96-0.97]	0.97 [0.86-0.98]		
$(LDL \ge 4.1 \text{ mmol/L } [24])$	15,201	11	2,031 (13.3%)	0.90 [0.90-0.97]	0.97 [0.80-0.96]		
High total cholesterol	16,586	11	3,206 (19.3%)	0.96 [0.96-0.96]	0.96 [0.83-0.99]		
$(totchol \ge 6.2 \text{ mmol/L } [24])$ Low HDL cholesterol	10,500	11	5,200 (15.570)	0.50 [0.50 0.50]	0.50 [0.05 0.55]		
	16,506	11	7,414 (44.9%)	0.95 [0.95-0.96]	0.95 [0.85-0.96]		
$(HDL \le 1.3 \text{ mmol/L } [24])$ Diabetes	10,000		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		0.00 [0.00 0.00]		
(TRUE/FALSE)	18,841	16	4,034 (21.4%)	0.94 [0.93-0.9]	0.86 [0.72-0.98]		
Metabolic syndrome							
(TRUE/FALSE)	7,811	6	3,452 (44.2%)	0.93 [0.92-0.94]	0.86 [0.71-0.93]		
Sex (male)							
(TRUE/FALSE)	21,610	23	10,281 (47.6%)	0.92 [0.92-0.93]	0.91 [0.73-0.99]		
Lipid medication							
(TRUE/FALSE)	17,707	14	5,783 (32.7%)	0.91 [0.90-0.91]	0.85 [0.77-0.94]		
Low age	21 510	22					
(age < 45 y.o.)	21,519	23	3,353 (15.6%)	0.89 [0.88-0.90]	0.80 [0.55-0.85]		
High hsCRP	5,180	8	1,548 (29.9%)	0.86 [0.84-0.86]	0.81 [0.7-0.86]		
(hsCRP > 3mg/L [25])	5,100	0	1,540 (25.570)	0.00 [0.04 0.00]	0.01 [0.7 0.00]		
Blood pressure lowering medication (TRUE/FALSE)	15,832	13	7,234 (45.7%)	0.82 [0.81-0.83]	0.71 [0.51-0.84]		
High age	10,002	10	,,201 (1017,6)	0.02 [0.01 0.00]			
(age ≥ 65 y.o.)	21,519	23	8,273 (38.4%)	0.82 [0.80-0.83]	0.73 [0.64-0.86]		
Obesity status							
(BMI \geq 30 kg/m ² and w.c. \geq 102 cm [M]							
$BMI \ge 30 \text{ kg/m}^2$ and w.c. $\ge 93 \text{ cm} [F] [26])$	19,322	18	3,135 (16.2%)	0.78 [0.75-0.80]	0.76 [0.69-0.81]		
Low hemoglobin							
$(hgb \le 6.67 \text{ mmol/L } [M];)$				(
$hgb \le 7.62 \text{ mmol/L [F] [27]}$	10,508	6	1,299 (12.4%)	0.76 [0.73-0.78]	0.72 [0.63-0.75]		
Low white blood cells	0.400	C					
$(\text{wbc} \le 4.5 \times 10^9 \text{ L} [27])$	9,496	6	818 (8.6%)	0.73 [0.69-0.76]	0.61 [0.5-0.71]		
Current smoking	21,662	23	8,276 (38.2%)	0.71 [0.70-0.72]	0.63 [0.48-0.78]		
(TRUE/FALSE)	21,002	23	8,270 (38.270)	0.71[0.70-0.72]	0.03 [0.48-0.78]		
Alcohol consumption	16,430	13	11,763 (71.6%)	0.71 [0.70-0.73]	0.60 [0.48-0.70]		
(TRUE/FALSE) Middle age			==,,				
$(45 \text{ y.o.} \ge \text{Age} < 65 \text{ y.o.})$	21,519	23	9,893 (46.0%)	0.71 [0.70-0.72]	0.58 [0.50-0.69]		
High pressure							
(systolic \geq 140 mmHg and							
$(\text{system} \ge 140 \text{ mmHg and})$ diastolic $\ge 90 \text{ mmHg [24]})$	17,509	12	7,765 (44.3%)	0.68 [0.66-0.69]	0.60 [0.52-0.76]		
$\text{urasion} \leq 50 \text{ mining } [24])$	17,505	12	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0.00 [0.00-0.05]	0.00 [0.52-0.70]		

samples: number of participants; # cohorts: number of cohorts that we could use for training the models and for the evaluation using 5-Fold Cross Validation (5-Fold CV); # TRUE POSITIVES: the number of samples with original variable equal to TRUE; Results (AUC): 5-Fold CV= the mean AUCs of the 5-Fold CV) and LOBOV= the mean AUCs of the Leave One Biobank Out Validation weighted based on the size of the testing biobank. [M]: male, or [F]: female specific criteria, eGFR=estimated glomerular filtration rate, w.c=waist circumference, hgb=haemoglobin, wbc=white blood cells.

160

161 Metabolic surrogates show dependencies mimicking the conventional clinical variables

162 Given that all models are trained on a relatively limited set of metabolic markers, we 163 investigated to what extent the produced models and predictions show mutual dependencies. 164 For this purpose, we first visualized the coefficients (betas) of the logistic Elastic-NETs 165 (Figure 2) to show the relative importance of the metabolites within each of the prediction models. While the selection of variables for the models shows a distinct pattern, we also note 166 167 some similarities, as quantified by the correlations between the model coefficients (Figure S3). 168 Overall, we note a clear preference for the models to include metabolites of the classes 169 "Lipoproteins" and "Lipids and related measures" over "Amino Acids". In addition, we note 170 that the models of related phenotypes also display some resemblances in the employed features, 171 for instance 'lipid medication' and 'blood pressure lowering medication' share some model characteristics. 172

173 We next evaluated correlations between the outputs of our models, from here on referred 174 to as the 'metabolic surrogates' (Figure 3) and compared these to correlations between the 175 original clinical variables (Figure S1B) in the BBMRI.nl data set. Overall, we observe that the 176 model outputs show correlation patterns and groupings that largely mimic that of the original 177 variables. For instance, model outputs trained on variables related to weight problems, i.e. 'obesity', 'diabetes', 'metabolic syndrome', show high mutual correlations, and moreover are 178 179 grouped with model outputs trained on medication usage, i.e. 'lipid medication' and 'blood 180 pressure lowering medication'. Although we observe some correlations between the outputs 181 of our different age predictors i.e. 'low age', 'middle age', 'high age', we observe that 'high age' is grouped with the models for 'high hscrp', 'lipid medication' and 'blood pressure 182 183 lowering medication', while 'middle age' is grouped with 'current smoking' and 'alcohol use'

- 184 and 'low age' with 'low white blood cell count'. This suggests that at different ages, different
- 185 conventional clinical variables play a role in physiology; an aspect well-known from literature
- 186 [28]–[30]. Overall, this indicates that our models show mutual dependencies similar as we
- 187 observe for the original clinical variables.







Figure 2: ElasticNETs metabolites relative importance. The heatmap reports the relative importance of the metabolites (columns) in each of the trained models (rows). Prior to visualization, metabolite coefficients were scaled per model by dividing them by the coefficients' sum in each model to create the relative importance per model. Top: Metabolites were then ordered based on the sum of their importance across all models. In addition, the models are clustered on the similarity between relative importance. Bottom: Categorized metabolic measures: "Amino acids", "energy metabolism", "infammation", "lipoproteins" and "lipids and related measures". Right: Mean AUCs of the 5-FoldCV in a scale of purple.



196 197	
197	Figure 3: Heatmap of pairwise correlations of the metabolic based surrogate markers calculated in BBMRI-NL
198	The heatmap of correlations of the metabolic surrogate values of the 19 successful models, clustered based on the
199	correlation levels, between the imputed metabolic surrogate levels within BBMRI-NL.
200	

201 **Projection in an independent study demonstrates model accuracy**

We performed a more extensive evaluation of the surrogate values by employing
Nightingale ¹H-NMR metabolomics and phenotypic data of the Leiden Longevity Study, a

204 cohort excluded from the training and testing sets [20]. The Leiden Longevity Study is a two-205 generation family-based cohort consisting of highly aged parents (LLS-SIBS, 851 individuals, age median = 92 years old) their middle-aged offspring and their partners (LLS-PAROFF, 206 207 2,307 individuals, age median = 59 years old). Using our models to project metabolic 208 surrogates in the LLS-PAROFF gave an independent confirmation that conventional clinical 209 variables can be readily captured by ¹H-NMR metabolomics. Splitting the surrogate values by 210 the actual labels of the corresponding binary phenotypes generally showed a good separation 211 for important cardio-metabolic variables like 'sex', 'diabetes status', 'lipid medication', 212 'blood pressure lowering medication' and 'high LDL cholesterol' (Figure 4A and S4), emphasizing the suitability of our models for quality control purposes or to impute missing 213 214 data. For instance, model results for 'sex' could be applied to verify absence of sample mixups (t. stat = 44.58, $p = 1.4x10^{-313}$). In addition, surrogate values seem informative on the 215 216 nature of the missingness of phenotypic data. For instance, participants with a missing diabetes 217 status typically had metabolic surrogate values similar to those of participants without diabetes 218 (diabetes: $\mu_F = 0.05$, $\mu_T = 0.41$, $\mu_{NA} = 0.08$), suggesting that a missing diabetes status 219 generally implies 'non-diabetics' in this cohort. Similar observations were made for medication status (lipidmed: $\mu_F = 0.22$, $\mu_T = 0.45$, $\mu_{NA} = 0.21$ and blood_pressure_lowering_med: 220 $\mu_F = 0.44, \mu_T = 0.55, \mu_{NA} = 0.46$): participants with missing statuses were more similar to 221 222 non-medication users than medication users. In contrast, participants with missing values in 223 LDL cholesterol had surrogate values indicating "at risk" levels of LDL cholesterol 224 (high_ldl_chol: $\mu_F = 0.07$, $\mu_T = 0.66$, $\mu_{NA} = 0.14$). Lastly, our surrogates also allow for 225 explorative analyses of totally unrecorded variables. For instance, the 'metabolic syndrome' 226 surrogate indicates participants who are more likely to have metabolic syndrome, a status 227 which was not assessed in the LLS-PAROFF cohort (Figure 4A).


228

229 Projection in the Leiden Longevity Study shows associations with additional cardio-

230 metabolic phenotypes

231 Within the LLS-PAROFF we had access to several additional variables pertaining to one's 232 cardio-metabolic risk namely hormone levels of insulin, leptin, and adiponectin, as well as the 233 levels of the inflammatory marker interleukin 6 (IL6) (Figure 4B). As expected, insulin levels 234 correlated positively with most surrogate cardio-metabolic risk factors and endpoints, including 'diabetes' [31] $(r = 0.28, p = 7.6x10^{-42})$ and even more so with 'metabolic 235 syndrome' (r = 0.52, $p = 1.4x10^{-152}$) [32]. Conversely, both 'low wbc' and 'low age' were 236 237 inversely correlated with insulin, both reflecting the associations with decreased insulin 238 sensitivity in those with high white blood cell counts [33] or in old age [34]. A similar analysis 239 for the satiety hormone leptin showed the strongest positive correlations with 'obesity' [35] $(r = 0.3, p = 5.6x10^{-49})$, but also with 'high hscrp'[36] $(r = 0.29, p = 4.2x10^{-46})$. A 240 241 significant correlation with leptin was also found for 'metabolic syndrome' [37] $(r = 0.15, p = 3.9x10^{-13})$, yet not 'diabetes' [38] (r = 0.02, p = 0.33). In line with 242 previous studies, higher levels of the adiponectin hormone generally correlated with lower 243 values of the surrogates, most prominently with 'low hdlchol' (r = -0.47, $p = 8.6x10^{-123}$) 244 and 'high triglycerides' $(r = 0.3, p = 1.1 \times 10^{-48})$ [39]. Higher adiponectin levels were 245 positively correlated with 'low wbc'(r = 0.35, $p = 6.1 \times 10^{-68}$), reproducing the previously 246 reported association by Matsubara et al [40]. Levels of the inflammatory marker IL6 were most 247 prominently positively correlated with the surrogates 'high hscrp' [41] (r = 0.31, p =248 $8.7x10^{-51}$), 'current smoking' [42] (r = 0.2, $p = 3.9x10^{-13}$), and inversely correlated with 249 'low wbc' [43] $(r = -0.19, p = 3.9x10^{-13})$. When comparing these correlation patterns 250 251 obtained with the surrogate values (Figure 4B) with those you would get when using the original values (Figure S7A), we generally notice highly similar trends ($r \sim 0.83$, Figure 252 253 S7F), as exemplified for leptin (Figure 4C). Overall, these findings indicate that our metabolic

surrogates faithfully reproduce the original clinical variables in their association with insulin,



255 leptin, adiponectin and IL6.

Figure 4: Metabolic surrogates applied to LLS-PAROFF: [A] Paired boxplots show surrogate values split between the TRUE/FALSE (0/1) in the original values of the clinical variables (*** p value ≤ 0.001). For metabolic syndrome the original variables are entirely missing, so no p-value is reported. [B] Heatmap of the correlations between the metabolomic surrogates (columns) and four additional cardio-metabolic biomarkers (rows) available in LLS-PAROFF. Values of insulin, leptin, adiponectin and IL6 were transformed with a natural logarithm. [C] Paired bar plots comparing the correlations computed between leptin and the metabolic surrogates (blue) and those computed between leptin and the values of the original clinical variables (red) the surrogates are trained to predict.


264 Metabolic surrogates to explore confounders in Metabolome Wide Association Studies

We next explored the use of ¹H-NMR metabolic surrogates to complement missing 265 phenotypic data in metabolome-wide association studies (MetaboWAS). As an example, we 266 evaluated the association of metabolic markers with Type 2 Diabetes status (T2D) in absence 267 268 of information on a known potential confounder: BMI. We designed a controlled experiment to evaluate to what extent surrogate 'obesity' can replace BMI, using data of 1,697 individuals 269 of LLS-PAROFF with complete metabolomic, BMI and diabetes status, of which 79 are 270 271 diagnosed with type 2 diabetes. 272 First, we ascertained that BMI was indeed a confounder, also within the LLS-PAROFF, by showing that BMI associated with the outcome (Type 2 Diabetes status, *t-test*= -7.83, p =273

 8.25×10^{-15} Figure S8A), as well as many of the determinants (147 significant metabolites

275 after correction, see Methods) of the MetaboWAS. Concomitantly, further adjustment of the 276 MetaboWAS on T2D for BMI drastically reduced the number of significant metabolites. To compare, when adjusting for age and sex we identified 136 metabolites significantly associated 277 278 with diabetes status, whereas further adjustment for BMI identified 80 significant metabolites (Figure S9B Comparison 1). Next, we performed the same association analyses using the 279 'obesity' surrogate as confounder. Similar to BMI, also the 'obesity' surrogate is significantly 280 higher in diabetics as compared to non-diabetics (*t-test* = -11.2, $p = 2.48 \times 10^{-28}$ Figure S8B) 281 and was associated with many of the metabolites (176 significant associations). Further 282 283 adjusting the MetaboWAS on T2D for 'obesity' reduced the number of significant metabolites 284 to 66 (Figure S9B Comparison 2).

285 We then investigated to what extent adjusting for BMI or adjusting for the 'obesity' surrogate yields similar metabolite markers to T2D associations, by comparing the obtained 286 estimates from both models (Figure 5). Overall, highly similar ($r^2 = 0.902$) associations 287 288 between metabolic markers and T2D are found for both models, with glucose being the most significantly associated marker in both ($p = 9.43 \times 10^{-28}$ when correcting for BMI and p =289 $1.6x10^{-26}$ correcting for 'obesity'). While most metabolites reported to be significantly 290 associated with T2D overlap between the two models (62 out of 227; in purple), some 291 292 discrepancies were observed, particularly at the significance threshold. When correcting for 293 BMI, 18 significant metabolic markers were identified, that were not identified when correcting 294 for 'obesity' (red dots, false negative rate ~ 0.11). Conversely, 7 metabolites were deemed 295 significantly associated with diabetes status when adjusting for 'obesity', but not when 296 adjusting for BMI (blue dots, false positive rate ~ 0.027). Nevertheless, overall, the differences 297 in estimated effects remain small, indicating that metabolic surrogates may prove useful to 298 account for missing data in epidemiological studies.




Significant in both • Significant in metaboWAS correcting for BMI • Significant in metaboWAS correcting for s. cobesity
 Figure 5: Comparison between the estimated coefficients of metaboWAS on T2D adjusted for BMI or for surrogate
 obesity'. On the x-axis the metaboWAS for diabetes adjusting for BMI and on the y-axis the metaboWAS for diabetes adjusted for surrogate obesity. The data set composed of 1,697 individuals, 79 of which are diabetics. Estimated coefficients for each metabolite (points) are colored based on their significance in the two models: purple: significant in both; red: significant when adjusted for SUT only; blue: significant when adjusted for surrogate obesity only; black never significant. Lower right corner: a contingency table with the number of significant and non-significant metabolites identified using the two models.

306 Metabolic surrogates associate with incident all-cause mortality in older individuals


307 Next, we evaluated whether metabolic surrogates are indicative of health at old age, by 308 associating these with all-cause mortality in a nonagenarian subsample of the Leiden Longevity 309 Study (LLS SIBS; 844 individuals, median age at baseline: 92 years old) (Figure 6A). Using 310 a Cox proportional hazards model adjusted for sex and age at inclusion for each of the 19 311 metabolic surrogates (Materials and Methods), we observed that 13 out of the 19 surrogates 312 associated significantly with all-cause mortality (Figure 6, 'all'). In line with previous reports, 313 we observed the largest effect sizes with the surrogate levels of 'high age', 'medications usage', 'diabetes status', 'high hscrp' and 'hemoglobin'. As previous studies have reported 314 315 sex-specific associations for these clinical variables with all-cause mortality, we conducted a 316 stratified analysis [44]–[50]. Although, the direction of association with all-cause mortality 317 remains generally the same between men and women, the strengths and their significance are in some cases different. For instance, the surrogate 'diabetes' is associated with a higher risk 318

on mortality in men (HR = 1.23, $p = 6.42 \times 10^{-4}$), than for women (HR = 1.11, $p = 3.1 \times 10^{-3}$), the same goes for '*blood pressure lowering medication*' (men: HR = 1.3, $p = 1.13 \times 10^{-5}$, women: HR = 1.1, $p = 6.39 \times 10^{-3}$). In contrast, '*low hemoglobin*' is associated with a higher risk in women (HR = 1.5, $p = 1.95 \times 10^{-13}$), than men (HR = 1.37, FDR = 2.42×10^{-8}).

323 To identify the minimal set of metabolic surrogates independently associating with allcause mortality, we performed a stepwise (forward/backward) cox regression, adjusted for age 324 325 at sampling, in the LLS-SIBS dataset (Figure 7A-B), stratified for sex. The surrogates '*high* hsCRP' and 'high triglycerides' emerged as independent predictive features in both male and 326 327 female models, associated with an increased and decreased risk respectively. While eight surrogates contributed to the male model, including 'lipid medication', 'high age', 'high 328 hsCRP' and 'low hdlchol', only three surrogates contributed to the mortality prediction in 329 330 females: 'high hsCRP', 'high triglycerides' and 'low hemoglobin'. These findings are in line 331 with previous reports that different risk factors seem to predict survival up to the highest ages 332 for the different sexes [51]–[53].



LLS_SIBS - Time to Death associations (corrected for age+sex)



337

[A]

	LL3-3163. 30	spwise Cox regression of Th	le to Death in males us	ing surroyates	
age	(N=326)	(1.06 - 1.16)		⊢∎	<0.001 ***
s_diabetes	(N=326)	(1.02 - 1.34)		⊢−−− +	0.021 *
s_lipidmed	(N=326)	(1.14 - 1.64)			
s_blood_pressure_lo	wering_med (N=326)	0.72 (0.56 - 0.93)		-	0.012 *
s_high_age	(N=326)	1.37 (1.16 - 1.62)			<0.001 ***
s_obesity	(N=326)	0.84 (0.72 - 0.97)			0.021 *
s_high_hscrp	(N=326)	1.47 (1.26 - 1.72)		·	■ <0.001 ***
s_high_triglycerides	(N=326)	0.86 (0.77 - 0.97)			0.012 *
s_low_hdlchol	(N=326)	1.24 (1.06 - 1.45)		⊦ B	- 0.006 **
(cluster)	(N=326)	reference		•	
# Events: 325; Global µ AIC: 3035.29; Concord	o-value (Log-Rank): 7.1056e-20 lance Index: 0.68	0.6	0.8	1 1.2 1.4	1.6 1.8
338 339 340	and females [omposite meta B], in LLS-SII or family relati	3S, compos	ed using the su	rrogate met

ion for Time to De

[B]

LLS-SIBS: Stepwise Cox regression for Time to Death in fem

age	(N=518)	1.1 (1.07 – 1.15)			⊢	■→				<0.001 ***
s_high_hscrp	(N=518)	(1.11 – 1.35)				H	-			<0.001 ***
s_high_triglycerides	(N=518)	0.9 (0.82 - 0.98)		 i						0.012 *
s_low_hgb	(N=518)	1.4 (1.20 - 1.53)					ļ			┥ <0.001 ***
(cluster)	(N=518)	reference								
# Events: 513; Global p-value (Li AIC: 5349.1; Concordance Index.		0	.8 0	9	1	.1 1	2 1	3 1.	4 1.5	1.6

LLS-SIBS: Ster

ise Cox rear

Figure 7: Composite metabolomics predictors of incident all-cause mortality: Predictors of time to death for males [A] and females [B], in LLS-SIBS, composed using the surrogate metabolic measures, sex and age. "(cluster)" refers to the variable controlling for family relationships (methods). Cox regression models were made using a step forward/backward selection.

341 **Discussion**

342 Missing phenotypic data is common in large epidemiological studies and in particular impedes biomarker research in older individuals. We employed ¹H-NMR metabolomics data 343 344 as a single source of information to successfully impute 19 out of 20 conventional clinical 345 variables that mainly relate to cardio-metabolic health. We highlighted the potential of our 346 imputation models for conventional clinical variables with three application scenarios. First, we applied our models to an independent study, the Leiden Longevity Study, demonstrating 347 348 that we can reconstruct conventional clinical variables at high accuracy. Secondly, we showed 349 the value of metabolic surrogates in omics studies when data on potential confounders is 350 missing. Finally, we exemplified how metabolic surrogates can be used to explore risk factors 351 of health in older individuals by showing that multiple metabolic surrogates are independently 352 predictive of all-cause mortality.

353 Using logistic ElasticNET regression models we were able to reconstruct a broad range of 354 conventional clinical variables assessed in BBMRI-NL pertaining to physiological measures, 355 body composition measures, environmental exposures, inflammatory factors, medication usage 356 blood cell composition, lipids metabolism, and also clinical endpoints. For this purpose, we 357 constructed composite variables that may better capture particular aspects of health, for 358 instance, our 'obesity' variable integrates body mass index, waist circumference and sex to 359 create a sex-specific measure for overweight. In addition, we chose to construct binary 360 representations of the continuous clinical variables for several reasons. First, we binarized 361 continuous variables for a practical reason – to be able to judge all models on the same criteria. 362 Secondly, predicting continuous variables using linear ElasticNET regression models 363 emphasizes the prediction of the extremes of a phenotypic distribution, i.e. the model will fit the most atypical participants, whereas the current approach emphasizes to predict the 364 365 commonly populated phenotypic range in which participants become at risk. Thirdly, our 366 models output a posterior probability that indicates the likelihood (a continuous score) of a 367 sample belonging to one of two labels, e.g. *obese/non-obese*. In effect, these posteriors 368 reconstitute part of the information lost when dichotomizing continues variables, as 369 exemplified by the observed correlation patterns between surrogates that mimic the correlation 370 patterns between the original variables.

371 Our pre-trained models for conventional clinical variables allow for the imputation of 372 missing datapoints in partially incomplete phenotypic variables, and moreover they offer the 373 opportunity to explore associations with completely unobserved phenotypic variables. The 374 latter is very much in line with the current use of PolyGenic Scores (PGSs) [54]–[56]. A PGS 375 captures the genetic propensity of the realization of a particular polygenic phenotype. Nearly a 376 thousand PGSs have been collected [57], which can be used to systematically explore 377 correlations between a measured variable of interest and a wide array of phenotypes-by-proxy 378 in genetic studies. We propose a similar use for metabolic surrogates in large metabolomics 379 studies, yet with two noteworthy distinctions. Whereas PGSs can arguably be used to tease out 380 causality in so-called Mendelian Randomization studies [58], metabolomic surrogates cannot. 381 In contrast, while PGSs often only explain a very modest part of their respective phenotypes, 382 metabolic surrogates explain a much larger part, thus enabling different types of applications. We illustrated this in our second application scenario where we showcased the use of surrogates 383 384 to explore potential confounding by non-assessed phenotypic variables in omics studies. While 385 use of actual phenotypic variables will always be preferred over metabolic surrogates, the 386 availability of these metabolic surrogates can thus be used to direct replication efforts or to 387 inform the design of new or follow-up studies.

Besides anthropometric measures and other physiological characteristics, the blood ¹H-NMR metabolome was previously also shown to capture aspects directly pertaining to health outcomes. In particular, we and others have previously reported ¹H-NMR metabolomics-based

19

391 risk estimators of cardiometabolic disease [59], [60], pneumonia and COVID infection [61], 392 and all-cause mortality [17]. While this clearly illustrates the vast potential of the blood ¹H-393 NMR metabolome as a universal readout for health outcomes, it also raises the question what 394 factors give rise to metabolomic profiles associated with adverse outcomes. Given that the find 395 variation in the ¹H-NMR metabolome is the result of a complex interplay of both environmental 396 and genetic factors, we evaluated whether our surrogates might give us a first indication. To 397 do so, we tested which of our surrogates might be indicative of all-cause mortality in an elderly 398 subset of the LLS-study. Intriguingly, by employing our pre-computed models as well as when 399 we built multi-variate cox-regression models for time-to-death, we find metabolic surrogates 400 that relate to conventional clinical risk factors known to associate with mortality risk at old 401 age. Moreover, sex-stratified analyses recapitulate some of the known differences in mortality associations observed at old age, with for instance many more risk factors independently 402 403 associated for mortality in males, as compared to females. These results illustrate that 404 metabolic surrogates can aid in the interpretation of metabolomics-based risk estimators.

405 This study has several limitations. LOBOV analyses revealed that the trained surrogates 406 may show study-specific effects that may relate to employed procedures of data collection or 407 sample storage of the cohorts under investigation. While these artifacts may be addressed using 408 batch-correction algorithms [62], or employing deep learning models for the prediction tasks, 409 we note that differences between studies may also be due to valid biological reasons, such as 410 differences in inclusion criteria. Secondly, the number of biomarkers captured by the targeted 411 NMR platform is small compared to the whole human metabolome (over 19,000 according to 412 the Human Metabolome Database [63]). Therefore, more elaborate, though typically more 413 costly, high-throughput platforms might reach even higher accuracy levels. However, 414 employing more biomarkers also has the danger of overfitting to the aforementioned study-415 related artifacts.

In conclusion, we have shown that the blood metabolome assayed by ¹H-NMR metabolomics can successfully capture a broad set of conventional clinical variables opening various possibilities to exploit surrogates of these clinical variables in in large epidemiological and clinical studies.

420 MATERIALS and METHODS

421

422 **1. Study populations**

423 The samples used for the current study are part of the BBMRI-NL Consortium (Dutch 424 Biobanking and BioMolecular resources and Research Infrastructure, https://www.bbmri.nl/), 425 which includes the following 28 Dutch biobanks: ALPHAOMEGA, BIOMARCS, CHARM, 426 CHECK, CODAM, CSF, DMS, DZS WF, ERF, FUNCTGENOMICS, GARP, HELIUS, 427 HOF, LIFELINES, LLS PARTOFFS, LLS SIBS, MRS, NESDA, PROSPER, RAAK, RS, STABILITEIT, STEMI GIPS-III, TACTICS, TOMAAT, UCORBIO, VUMC ADC, 428 429 VUNTR. A description of the cohorts included is provided in the Supplementary Materials. 430 Ethics committees approved the protocols for these studies in all the involved institutes, and 431 all participants provided informed consent. The whole data set contains samples of ~31,000 432 individuals.

- 433
- 434

2. Metabolomic measurements

435 The present study included metabolite concentrations measured in EDTA plasma 436 samples using the high-throughput proton Nuclear Magnetic Resonance (¹H-NMR) 437 metabolomics (Brainshake Ltd./Nightingale Health[©], Helsinki, Finland). This device provides the quantification of routine lipids, lipoprotein subclasses, fatty acid composition and various 438 439 low-molecular weight metabolites including amino acids, ketone bodies and glycolysis-related 440 metabolites in molar concentration units. Details about the methods and applications of the 441 NMR platform have been provided previously [22], [64]. The total amount of metabolic 442 variables reported is 226 for EDTA plasma samples, including the ratios and derived measurements, but only 63 of these were considered for the current study, to prevent overfitting 443 444 [21], [59]. The list comprises the total lipid concentrations, fatty acids composition and low-445 molecular-weight metabolites including ketone bodies, glycolysis-related metabolites, aminoacids and metabolites related to immunity and fluid balance (See the Supplementary Materialsfor a full list).

448 449

3. Data Pre-processing

450

a. Pre-processing of metabolomics data

451 We included in our analyses all the cohorts reporting on all the 63 metabolic biomarkers, 452 therefore we omitted CODAM (N = 254) and VUNTR (N = 3,896), which are missing 453 acetoacetate and glutamine, respectively. We also decided to not consider the metabolites with 454 low detection rates in more than one cohort (3-hydroxybutyrate) or which frequently failed to reach the minimum detection threshold (XL VLDL L, XXL VLDL L, L VLDL L, 455 456 XL HDL L, L HDL L). We removed outlier samples with 1 or more missing metabolic measure (232 removed samples), 1 or more zeroes per sample (74 removed samples) and 457 458 samples with any metabolite concentration level more than 5 standard deviations away from 459 the overall mean per metabolomic variable (604 removed samples). The remaining 551 missing 460 values in the dataset were imputed using the function nipals of the R package pcaMethods, and 461 we z-scaled the metabolic measures across all samples to have comparable concentration levels between metabolites. The final data matrix comprised 26,107 samples across 56 metabolic 462 463 variables. For more details, see Supplementary Materials. The number of samples used to train 464 a predictor for a clinical variable depended on the number of samples missing this phenotypic information (Table 1). More information about the range of each phenotype within each 465 466 biobank can be found in the Supplementary Materials.

467 468

b. Binarization of the clinical variables

To emphasize the relevant clinical conditions, we used clinical thresholds to obtain dichotomous variables out of the set of the available continuous risk factors, separating between "normal" and "at risk" levels for each risk factor (in *Table1* and in the Supplementary
Document 3).

473

c. Composed clinical variables

474 We chose to include some composed clinical variables: 1) LDL cholesterol, which was 475 calculated using the Friedewald equation [65] with the measured hdl cholesterol, triglycerides 476 levels and total cholesterol; 2) eGFR (estimated Glomerular Filtration Rate), which is a 477 measure for the kidney filtration rate of an individual, was calculated using the creatinine-based 478 CKD-EPI equation [66]; 3) obesity, which is a binary variable describing if a person is 479 clinically obese or not variable that uses BMI, waist circumference and sex based on the fniding 480 of Flint et al. [26]; 4) high pressure, a binary variables which defines high blood pressure by 481 using systolic and diastolic blood pressure [24]; 5) low hgb (low hemoglobin), which is a 482 binary variables describing 'at risk' levels of hemoglobin by using hemoglobin and sex [27].

483 484

4. Estimation of the metabolic surrogates

485

a. Method selection

486 The models considered for each Risk Factor are logistic regression models:

- 487
- 488

489

$$\hat{c}_i \sim \beta_0 + \sum_{j=1}^{56} \beta_j m_j \beta_1 + \varepsilon_i$$

in which c_i represent one of clinical variables of interest, m_j one of the 56 measured metabolites, β_j the regression coefficient, and ε_i the normal distributed reconstruction error. The regression coefficients are found by minimizing the ordinary least squares error, with the addition of an elastic net regularization term for the coefficients:

494

495 496

$$\boldsymbol{\beta}(\alpha, \lambda) = argmin_{\beta}((c_i - \hat{c}_i)^2 + \lambda[\alpha \|\boldsymbol{\beta}\|_1 + (1 - \alpha)\|\boldsymbol{\beta}\|_2])$$

497 in which $\lambda \in (0, \infty)$ represents the "shrinkage parameter" and $\alpha \in (0,1)$ is the mixing 498 parameter balancing the L1 and L2 norm regularizations. We fixed the mixing parameter α at 499 0.5 for the predictive models, like previously done by other authors and optimized the500 shrinkage parameter using an inner-fold cross-validation scheme.

- 501
- 502

b. Training and validation procedure

503 We employed two training-evaluation procedures to get an unbiased estimate of the 504 models' possible performances (Figure 1). As a first scenario, we used a Double 5-Fold-Cross-505 Validation (5-Fold CV) with 5 repetitions. This procedure consists of two loops of 5FCV, one 506 internal and one external, in which we first split the dataset in testing (20%) and training (80%) 507 sets and then on the latter set we have another 5FCV repeated for 5 different times, which is 508 done for an unbiased tuning of the model (setting the correct λ parameter) that is finally trained 509 on the complete training dataset and tested on the left-out test data. Both 5-FoldCVs were done 510 such that the original distribution of each clinical variable is maintained as much as possible 511 (using the function *createFolds* from the R package *caret*). In the second training-testing 512 procedure, we applied a Leave-One-Biobank-Out-Validation (LOBOV), which consists of 513 holding out one of the biobanks with the considered variable available, which is then used as a 514 test set, while training on the remaining biobanks [16]. Also, in this setting, we applied a 5FCV 515 with 5 repetitions to tune the best model for each training set.

- 516
- 517

5. Metabolome wide association studies

We conducted Metabolome Wide Association Studies (MetaboWAS) using the middleaged cohort of the Leiden Longevity Study (LLS-PARTOFFs, 2,307 individuals, median age at baseline = 59 years old). As metabolites distributions are often skewed, we first transformed all metabolite measurements using a rank inverse normalization (RIN). Applying a PCA on the LLS-PARTOFFs dataset revealed that the first 40 principal components explain 99% of the variance in the metabolites (**Figure S9A**). Hence, the *p-value* of the MetaboWASes were Bonferroni corrected using 40 tests, i.e. a *p-value* designated significant when smaller than
0.00125 (0.05/40) [60]. We performed 5 different MetaboWASs.

- 526
- 527

6. Associations of the metabolic surrogates to all-cause mortality

We used Cox proportional hazards models with follow-up time as the time scale, to test for 528 529 associations between the metabolic surrogate measures and incident endpoints, i.e. all-cause-530 mortality in LLS-SIBS. We checked for associations adjusting for age and sex. To avoid bias 531 due to familial correlations from pedigrees, we used robust standard errors (calculated with the 532 Huber sandwich estimator) implemented in R coxph function. Considering that the population 533 in LLS-SIBS has a different inclusion criterium for men (age > 89 years old) and women (age 534 > 91 years old), we also evaluated associations separately in men and women. *P-values* were 535 corrected using Benjamini Hochberg separately for each selection (all individuals, men and 536 women) and considered significant the FDR < 0.05. To select potentially interesting metabolic 537 surrogate, we used a stepwise procedure for the Cox regression models, corrected for sex and 538 age. Starting from a model containing the full set of available variables, we removed or added 539 an unselected metabolic surrogate at each round based on the improvement on the model 540 calculated from the Akaike Information Criterion and considering the *p*-value of each variable 541 included in the model.

542

543 Acknowledgements

This work was performed within the framework of the BBMRI Metabolomics Consortium funded by BBMRI-NL (a research infrastructure financed by the Dutch government, NWO 184.021.007 and 184.033.111), by X-omics (NWO 184.034.019), VOILA (ZonMW 457001001) and Medical Delta (scientific program METABODELTA: Metabolomics for clinical advances in the Medical Delta). EvdA is funded by a personal grant of the Dutch

549	Research Council	(NWO; VEN	T: 09150161810095)	. A full list o	of acknowledgements	for all
-----	------------------	-----------	--------------------	-----------------	---------------------	---------

the contributing studies can be found in the Supplementary Material table S1.

551

552 Authors Contribution

- 553 EbvDA, DB, MJTR and PES conceived and wrote the manuscript. DB performed the analyses.
- EBvDA and MJTR verified and supervised the analyses. All authors discussed the results and
- 555 contributed to the final manuscript.
- 556

557 Competing interests

- 558 The authors declare that there are no competing interests.
- 559

560 **References**

- 561 [1] K. Strimbu and J. A. Tavel, 'What are Biomarkers?', *Curr. Opin. HIV AIDS*, vol. 5, no.
 562 6, pp. 463–466, Nov. 2010, doi: 10.1097/COH.0b013e32833ed177.
- 563 [2] R. Mayeux, 'Biomarkers: Potential uses and limitations', *NeuroRX*, vol. 1, no. 2, pp. 182–
 564 188, Apr. 2004, doi: 10.1602/neurorx.1.2.182.
- 565 [3] S. Naylor, 'Biomarkers: current perspectives and future prospects', *Expert Rev. Mol. Diagn.*, vol. 3, no. 5, pp. 525–529, Sep. 2003, doi: 10.1586/14737159.3.5.525.
- 567 [4] S. G. Liao *et al.*, 'Missing value imputation in high-dimensional phenomic data:
 568 imputable or not, and how?', *BMC Bioinformatics*, vol. 15, no. 1, p. 346, Nov. 2014, doi:
 569 10.1186/s12859-014-0346-6.
- 570 [5] A. Dahl *et al.*, 'A multiple-phenotype imputation method for genetic studies', *Nat. Genet.*,
 571 vol. 48, no. 4, Art. no. 4, Apr. 2016, doi: 10.1038/ng.3513.
- 572 [6] K. T. Do *et al.*, 'Characterization of missing values in untargeted MS-based metabolomics
 573 data and evaluation of missing data handling strategies', *Metabolomics*, vol. 14, no. 10,
 574 2018, doi: 10.1007/s11306-018-1420-2.
- 575 [7] M. J. Azur, E. A. Stuart, C. Frangakis, and P. J. Leaf, 'Multiple imputation by chained
 576 equations: what is it and how does it work?', *Int. J. Methods Psychiatr. Res.*, vol. 20, no.
 577 1, pp. 40–49, Feb. 2011, doi: 10.1002/mpr.329.
- 578 [8] M. R. Malarvizhi and D. A. S. Thanamani, *K-Nearest Neighbor in Missing Data* 579 *Imputation.*
- 580 [9] S. Cheng *et al.*, 'Potential Impact and Study Considerations of Metabolomics in
 581 Cardiovascular Health and Disease A Scientific Statement From the American Heart
 582 Association', *Circ. Cardiovasc. Genet.*, vol. 10, no. 2, Apr. 2017, doi:
 583 10.1161/HCG.0000000000032.

- 584 [10] J. Liu *et al.*, 'Integration of epidemiologic, pharmacologic, genetic and gut microbiome
 585 data in a drug-metabolite atlas', *Nat. Med.*, vol. 26, no. 1, pp. 110–117, Jan. 2020, doi:
 586 10.1038/s41591-019-0722-x.
- [11] L. M. 't Hart *et al.*, 'Blood Metabolomic Measures Associate With Present and Future
 Glycemic Control in Type 2 Diabetes', *J. Clin. Endocrinol. Metab.*, vol. 103, no. 12, pp.
 4569–4579, Dec. 2018, doi: 10.1210/jc.2018-01165.
- 590 [12] G. L. J. Onderwater *et al.*, 'Large-scale plasma metabolome analysis reveals alterations
 591 in HDL metabolism in migraine', *Neurology*, vol. 92, no. 16, pp. e1899–e1911, Apr.
 592 2019, doi: 10.1212/WNL.00000000007313.
- I. C. van den Munckhof *et al.*, 'Microbial Impact on Plasma Metabolites is Linked to the
 Cardiovascular Risk and Phenotypes', *Atheroscler. Suppl.*, vol. 32, pp. 118–119, Jun.
 2018, doi: 10.1016/j.atherosclerosissup.2018.04.366.
- 596 [14] D. Vojinovic *et al.*, 'Metabolic profiling of intra- and extracranial carotid artery
 597 atherosclerosis', *Atherosclerosis*, vol. 272, pp. 60–65, May 2018, doi:
 598 10.1016/j.atherosclerosis.2018.03.015.
- 599 [15] J. Tynkkynen *et al.*, 'Association of branched-chain amino acids and other circulating
 600 metabolites with risk of incident dementia and Alzheimer's disease: A prospective study
 601 in eight cohorts', *Alzheimers Dement.*, vol. 14, no. 6, pp. 723–733, 2018, doi:
 602 https://doi.org/10.1016/j.jalz.2018.01.003.
- [16] van den Akker Erik B. *et al.*, 'Metabolic Age Based on the BBMRI-NL 1H-NMR
 Metabolomics Repository as Biomarker of Age-related Disease', *Circ. Genomic Precis. Med.*, vol. 0, no. 0, doi: 10.1161/CIRCGEN.119.002610.
- 606 [17] J. Deelen *et al.*, 'A metabolic profile of all-cause mortality risk identified in an
 607 observational study of 44,168 individuals', *Nat. Commun.*, vol. 10, no. 1, pp. 1–8, Aug.
 608 2019, doi: 10.1038/s41467-019-11311-9.
- [18] J. E. Ho *et al.*, 'Metabolomic Profiles of Body Mass Index in the Framingham Heart Study
 Reveal Distinct Cardiometabolic Phenotypes', *PloS One*, vol. 11, no. 2, p. e0148361,
 2016, doi: 10.1371/journal.pone.0148361.
- 612 [19] M. J. Rist *et al.*, 'Metabolite patterns predicting sex and age in participants of the
 613 Karlsruhe Metabolomics and Nutrition (KarMeN) study', *PLoS ONE*, vol. 12, no. 8, Aug.
 614 2017, doi: 10.1371/journal.pone.0183228.
- [20] M. Schoenmaker *et al.*, 'Evidence of genetic enrichment for exceptional survival using a
 family approach: the Leiden Longevity Study', *Eur. J. Hum. Genet.*, vol. 14, no. 1, Art.
 no. 1, Jan. 2006, doi: 10.1038/sj.ejhg.5201508.
- 618 [21] P. Würtz *et al.*, 'Metabolic Signatures of Adiposity in Young Adults: Mendelian
 619 Randomization Analysis and Effects of Weight Change', *PLoS Med.*, vol. 11, no. 12, Dec.
 620 2014, doi: 10.1371/journal.pmed.1001765.
- [22] P. Soininen, A. J. Kangas, P. Würtz, T. Suna, and M. Ala-Korpela, 'Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics', *Circ. Cardiovasc. Genet.*, vol. 8, no. 1, pp. 192–206, Feb. 2015, doi: 10.1161/CIRCGENETICS.114.000216.
- [23] S. A. Williams *et al.*, 'Plasma protein patterns as comprehensive indicators of health',
 Nat. Med., vol. 25, no. 12, pp. 1851–1857, Dec. 2019, doi: 10.1038/s41591-019-0665-2.
- [24] E. Crimmins, S. Vasunilashorn, J. K. Kim, and D. Alley, 'BIOMARKERS RELATED
 TO AGING IN HUMAN POPULATIONS', *Adv. Clin. Chem.*, vol. 46, pp. 161–216,
 2008.
- [25] L. M. Biasucci, CDC, and AHA, 'CDC/AHA Workshop on Markers of Inflammation and
 Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use
 of inflammatory markers in patients with cardiovascular diseases: a background paper',

- 633Circulation, vol. 110, no. 25, pp. e560-567, Dec. 2004, doi:63410.1161/01.CIR.0000148983.88334.80.
- 635 [26] A. J. Flint *et al.*, 'Body mass index, waist circumference, and risk of coronary heart
 636 disease: a prospective study among men and women', *Obes. Res. Clin. Pract.*, vol. 4, no.
 637 3, pp. e171–e181, 2010, doi: 10.1016/j.orcp.2010.01.001.
- [27] L. Dean and L. Dean, *Blood Groups and Red Cell Antigens*. National Center for
 Biotechnology Information (US), 2005.
- [28] R. J. Glassock and C. Winearls, 'Ageing and the Glomerular Filtration Rate: Truths and
 Consequences', *Trans. Am. Clin. Climatol. Assoc.*, vol. 120, pp. 419–428, 2009.
- E. Pinto, 'Blood pressure and ageing', *Postgrad. Med. J.*, vol. 83, no. 976, pp. 109–114,
 Feb. 2007, doi: 10.1136/pgmj.2006.048371.
- [30] C. M. Schubert *et al.*, 'Lipids, lipoproteins, lifestyle, adiposity and fat-free mass during
 middle age: the Fels Longitudinal Study', *Int. J. Obes.*, vol. 30, no. 2, Art. no. 2, Feb.
 2006, doi: 10.1038/sj.ijo.0803129.
- [31] V. Saini, 'Molecular mechanisms of insulin resistance in type 2 diabetes mellitus', *World J. Diabetes*, vol. 1, no. 3, pp. 68–75, Jul. 2010, doi: 10.4239/wjd.v1.i3.68.
- [32] C. K. Roberts, A. L. Hevener, and R. J. Barnard, 'Metabolic Syndrome and Insulin
 Resistance: Underlying Causes and Modification by Exercise Training', *Compr. Physiol.*,
 vol. 3, no. 1, pp. 1–58, Jan. 2013, doi: 10.1002/cphy.c110062.
- [33] 'High White Blood Cell Count Is Associated With a Worsening of Insulin Sensitivity and
 Predicts the Development of Type 2 Diabetes | Diabetes'.
 https://diabetes.diabetesjournals.org/content/51/2/455 (accessed Feb. 09, 2021).
- [34] D. C. Muller, D. Elahi, J. D. Tobin, and R. Andres, 'The effect of age on insulin resistance
 and secretion: a review', *Semin. Nephrol.*, vol. 16, no. 4, pp. 289–298, Jul. 1996.
- [35] P. J. Enriori, A. E. Evans, P. Sinnayah, and M. A. Cowley, 'Leptin Resistance and
 Obesity', *Obesity*, vol. 14, no. S8, pp. 254S-258S, 2006, doi: https://doi.org/10.1038/oby.2006.319.
- [36] O. Ukkola and Y. A. Kesäniemi, 'Leptin and high-sensitivity C-reactive protein and their
 interaction in the metabolic syndrome in middle-aged subjects', *Metabolism*, vol. 56, no.
 9, pp. 1221–1227, Sep. 2007, doi: 10.1016/j.metabol.2007.04.019.
- [37] P. W. Franks *et al.*, 'Leptin Predicts a Worsening of the Features of the Metabolic
 Syndrome Independently of Obesity', *Obes. Res.*, vol. 13, no. 8, pp. 1476–1484, 2005,
 doi: https://doi.org/10.1038/oby.2005.178.
- [38] M. I. Schmidt *et al.*, 'Leptin and incident type 2 diabetes: risk or protection?',
 Diabetologia, vol. 49, no. 9, pp. 2086–2096, Sep. 2006, doi: 10.1007/s00125-006-0351 z.
- [39] E. Nigro *et al.*, 'New insight into adiponectin role in obesity and obesity-related diseases',
 BioMed Res. Int., vol. 2014, p. 658913, 2014, doi: 10.1155/2014/658913.
- [40] M. Matsubara, K. Namioka, and S. Katayose, 'Decreased plasma adiponectin
 concentrations in women with low-grade C-reactive protein elevation', *Eur. J. Endocrinol.*, vol. 148, no. 6, pp. 657–662, Jun. 2003, doi: 10.1530/eje.0.1480657.
- [41] T. B. Harris *et al.*, 'Associations of elevated Interleukin-6 and C-Reactive protein levels
 with mortality in the elderly**Access the "Journal Club" discussion of this paper at
 http://www.elsevier.com/locate/ajmselect/', *Am. J. Med.*, vol. 106, no. 5, pp. 506–512,
 May 1999, doi: 10.1016/S0002-9343(99)00066-2.
- [42] J. Helmersson, A. Larsson, B. Vessby, and S. Basu, 'Active smoking and a history of
 smoking are associated with enhanced prostaglandin F2α, interleukin-6 and F2isoprostane formation in elderly men', *Atherosclerosis*, vol. 181, no. 1, pp. 201–207, Jul.
 2005, doi: 10.1016/j.atherosclerosis.2004.11.026.

- [43] C. E. Byrne, A. Fitzgerald, C. P. Cannon, D. J. Fitzgerald, and D. C. Shields, 'Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes', *BMC Med. Genet.*, vol. 5, no. 1, p. 13, Jun. 2004, doi: 10.1186/1471-2350-5-13.
- [44] Y. Wang *et al.*, 'Sex differences in the association between diabetes and risk of
 cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic
 review and meta-analysis of 5,162,654 participants', *BMC Med.*, vol. 17, no. 1, p. 136,
 Jul. 2019, doi: 10.1186/s12916-019-1355-0.
- [45] K. M. Dale, C. I. Coleman, S. A. Shah, A. A. Patel, J. Kluger, and C. M. White, 'Impact of gender on statin efficacy', *Curr. Med. Res. Opin.*, vol. 23, no. 3, pp. 565–574, Mar. 2007, doi: 10.1185/030079906X167516.
- [46] Y. An, J. Jang, S. Lee, S. Moon, and S. K. Park, 'Sex-specific Associations Between
 Serum Hemoglobin Levels and the Risk of Cause-specific Death in Korea Using the
 National Health Insurance Service-National Health Screening Cohort (NHIS HEALS)', *J. Prev. Med. Public Health Yebang Uihakhoe Chi*, vol. 52, no. 6, pp. 393–404, Nov.
 2019, doi: 10.3961/jpmph.19.146.
- 698 [47] E. Prescott *et al.*, 'Mortality in women and men in relation to smoking', *Int. J. Epidemiol.*,
 699 vol. 27, no. 1, pp. 27–32, Feb. 1998, doi: 10.1093/ije/27.1.27.
- [48] P. Muennig, E. Lubetkin, H. Jia, and P. Franks, 'Gender and the Burden of Disease
 Attributable to Obesity', *Am. J. Public Health*, vol. 96, no. 9, pp. 1662–1668, Sep. 2006,
 doi: 10.2105/AJPH.2005.068874.
- [49] B. T. Palmisano, L. Zhu, R. H. Eckel, and J. M. Stafford, 'Sex differences in lipid and
 lipoprotein metabolism', *Mol. Metab.*, vol. 15, pp. 45–55, May 2018, doi:
 10.1016/j.molmet.2018.05.008.
- Y. Li *et al.*, 'Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis', *Atherosclerosis*, vol. 259, pp. 75–82, Apr. 2017, doi: 10.1016/j.atherosclerosis.2017.02.003.
- [51] J. Liang, J. M. Bennett, H. Sugisawa, E. Kobayashi, and T. Fukaya, 'Gender differences in old age mortality: roles of health behavior and baseline health status', *J. Clin. Epidemiol.*, vol. 56, no. 6, pp. 572–582, Jun. 2003, doi: 10.1016/s0895-4356(03)00060-712 x.
- [52] M. A. Davis, J. M. Neuhaus, D. J. Moritz, D. Lein, J. D. Barclay, and S. P. Murphy,
 'Health behaviors and survival among middle-aged and older men and women in the
 NHANES I Epidemiologic Follow-up Study', *Prev. Med.*, vol. 23, no. 3, pp. 369–376,
 May 1994, doi: 10.1006/pmed.1994.1051.
- Y. Zhang *et al.*, 'Gender difference in cardiovascular risk factors in the elderly with
 cardiovascular disease in the last stage of lifespan: The PROTEGER study', *Int. J. Cardiol.*, vol. 155, no. 1, pp. 144–148, Feb. 2012, doi: 10.1016/j.ijcard.2011.09.073.
- [54] F. Dudbridge, 'Power and Predictive Accuracy of Polygenic Risk Scores', *PLoS Genet.*,
 vol. 9, no. 3, Mar. 2013, doi: 10.1371/journal.pgen.1003348.
- [55] C. M. Lewis and E. Vassos, 'Prospects for using risk scores in polygenic medicine',
 Genome Med., vol. 9, Nov. 2017, doi: 10.1186/s13073-017-0489-y.
- [56] A. V. Khera *et al.*, 'Genome-wide polygenic scores for common diseases identify
 individuals with risk equivalent to monogenic mutations', *Nat. Genet.*, vol. 50, no. 9, Art.
 no. 9, Sep. 2018, doi: 10.1038/s41588-018-0183-z.
- [57] S. A. Lambert *et al.*, 'The Polygenic Score Catalog as an open database for reproducibility
 and systematic evaluation', *Nat. Genet.*, pp. 1–6, Mar. 2021, doi: 10.1038/s41588-02100783-5.

- [58] T. G. Richardson, S. Harrison, G. Hemani, and G. Davey Smith, 'An atlas of polygenic
 risk score associations to highlight putative causal relationships across the human
 phenome', *eLife*, vol. 8, doi: 10.7554/eLife.43657.
- P. Würtz *et al.*, 'Metabolite profiling and cardiovascular event risk: a prospective study
 of 3 population-based cohorts', *Circulation*, vol. 131, no. 9, pp. 774–785, Mar. 2015, doi:
 10.1161/CIRCULATIONAHA.114.013116.
- [60] A. V. Ahola-Olli *et al.*, 'Circulating metabolites and the risk of type 2 diabetes: a
 prospective study of 11,896 young adults from four Finnish cohorts', *Diabetologia*, vol.
 62, no. 12, pp. 2298–2309, 2019, doi: 10.1007/s00125-019-05001-w.
- [61] Nightingale Health UK Biobank Initiative, H. Julkunen, A. Cichońska, P. E. Slagboom,
 and P. Würtz, 'Metabolic biomarker profiling for identification of susceptibility to severe
 pneumonia and COVID-19 in the general population', *eLife*, vol. 10, p. e63033, May
 2021, doi: 10.7554/eLife.63033.
- [62] W. E. Johnson, C. Li, and A. Rabinovic, 'Adjusting batch effects in microarray expression
 data using empirical Bayes methods', *Biostatistics*, vol. 8, no. 1, pp. 118–127, Jan. 2007,
 doi: 10.1093/biostatistics/kxj037.
- [63] D. S. Wishart *et al.*, 'HMDB 4.0: the human metabolome database for 2018', *Nucleic Acids Res.*, vol. 46, no. Database issue, pp. D608–D617, Jan. 2018, doi: 10.1093/nar/gkx1089.
- [64] P. Würtz, A. J. Kangas, P. Soininen, D. A. Lawlor, G. Davey Smith, and M. Ala-Korpela,
 'Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale
 Epidemiology: A Primer on -Omic Technologies', *Am. J. Epidemiol.*, vol. 186, no. 9, pp.
 1084–1096, Nov. 2017, doi: 10.1093/aje/kwx016.
- [65] W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, 'Estimation of the Concentration of
 Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative
 Ultracentrifuge', *Clin. Chem.*, vol. 18, no. 6, pp. 499–502, Jun. 1972, doi:
 10.1093/clinchem/18.6.499.
- [66] Carrero Juan Jesus, Andersson Franko Mikael, Obergfell Achim, Gabrielsen Anders, and
 Jernberg Tomas, 'hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events
 in Patients With Myocardial Infarction: a Healthcare-Based Study', *J. Am. Heart Assoc.*,
- 760 vol. 8, no. 11, p. e012638, Jun. 2019, doi: 10.1161/JAHA.119.012638.
- 761